Showing results (91-100 of 119) with videos related to
Sort By:
Pageof 12
Blood|December 10, 2013
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistanceZe Tian, Padraig D'Arcy, Xin Wang, et al.Biochemical Pharmacology|January 7, 2022
Caffeic acid phenethyl ester targets ubiquitin-specific protease 8 and synergizes with cisplatin in endometrioid ovarian carcinoma cellsDiego Colombo, Laura Gatti, Linda Sjöstrand, et al.Nutrients|June 24, 2015
Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR StudyOla Brodin, Staffan Eksborg, Marita Wallenberg, et al.Investigational New Drugs|March 4, 2020
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myelomaEric K Rowinsky, Agne Paner, Jesus G Berdeja, et al.The Journal of Biological Chemistry|July 5, 2012
Autophagy is a protective mechanism for human melanoma cells under acidic stressMaria Lucia Marino, Paola Pellegrini, Giuseppe Di Lernia, et al.Frontiers in Cell and Developmental Biology|December 29, 2022
The deubiquitinase USP8 regulates ovarian cancer cell response to cisplatin by suppressing apoptosisCristina Corno, Padraig D'Arcy, Marina Bagnoli, et al.BMC Cancer|August 8, 2013
Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistanceMårten Fryknäs, Joachim Gullbo, Xin Wang, et al.Journal of the National Cancer Institute|April 5, 2017
Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem CellsRan Ma, Govindasamy-Muralidharan Karthik, John Lövrot, et al.International Journal of Oncology|July 16, 2004
A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancerMasahiro Takada, Akemi Kataoka, Masakazu Toi, et al.Scientific Reports|December 8, 2016
Iron chelators target both proliferating and quiescent cancer cellsMårten Fryknäs, Xiaonan Zhang, Ulf Bremberg, et al.Pageof 12